Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - nci_ncicdr0000552637-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Genetics of Skin Cancer
Skin Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Actinic Keratosis
Actinic keratosis is not cancer but is treated because it may develop into cancer. Treatment of actinic keratosis may include the following:Topical chemotherapy.Topical biologic therapy with imiquimod.Cryosurgery.Electrodesiccation and curettage.Dermabrasion.Shave excision.Photodynamic therapy.Laser surgery.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with actinic keratosis. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Skin Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (10 / 08 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Skin Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Skin Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000258035-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Skin Cancer Treatment
Skin Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about skin cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in which
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Intraocular Melanoma
The prognosis for any patient with recurring or relapsing disease is poor, regardless of cell type or stage. The question and selection of further treatment depends on many factors, including the extent of the lesion, age and health of the patient, prior treatment, and site of recurrence, as well as individual patient considerations. Surgical resection of metastases diagnosed subsequent to initial management of ocular melanoma in single-center, case series of highly selected patients has been reported. The extent to which the occasional favorable outcomes are the result of strong selection factors is not clear, so this approach cannot be considered standard.Clinical trials are appropriate, and eligible patients should be advised to consider participation in them whenever possible. Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent intraocular melanoma. The list of clinical trials can be
Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Melanoma
For more information from the National Cancer Institute about melanoma, see the following:Melanoma Home PageWhat You Need to Know About™ Melanoma and Other Skin CancersSkin Cancer PreventionSkin Cancer ScreeningSentinel Lymph Node BiopsyDrugs Approved for MelanomaBiological Therapies for CancerUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies)Targeted Cancer TherapiesFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Role of ObservationIris melanomas have relatively good outcomes with a 5-year survival rate of more than 95%. They are predominantly of the spindle-cell type and are usually smaller in size than posterior melanomas because of earlier detection. Conservative management is generally advocated whenever possible, but surgical intervention may be justified with unequivocal tumor growth or with extensive disease at initial examination.The management of small choroidal melanomas is controversial, and it is not clear whether treatment of small tumors prevents metastasis. The natural history of small choroidal melanoma is poorly understood. Small, pigmented, choroidal lesions cannot always be differentiated reliably on examination. Growth is a presumed indicator of malignant potential. The likelihood of progression from the time of diagnosis to the time when tumor growth warrants treatment has not been well characterized. Some ophthalmologists advocate